caa a22 4500 60549021X CHVBK 20210128100503.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10147-014-0674-6 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0674-6 Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma [Elektronische Daten] [Tatsuo Masubuchi, Yuichiro Tada, Shin-ichiro Maruya, Yoshiyuki Osamura, Shin-etsu Kamata, Kouki Miura, Chihiro Fushimi, Hideaki Takahashi, Daisuke Kawakita, Seiji Kishimoto, Toshitaka Nagao] Background: Salivary duct carcinoma (SDC) is a highly aggressive disease which often metastasizes to distant sites, and there is no established standard therapy for this systemic disease. Given that SDC is biologically similar to breast and prostate cancer, anti-androgenic receptor (AR) and anti-human epidermal growth factor receptor 2 (HER2) therapies have the potential to exert effects, not only on patients with breast and prostate cancer but also on those with SDC. Methods: The expression levels of HER2, epidermal growth factor receptor (EGFR), Ki-67, and AR were assessed in 32 patients with SDC, and their correlations with overall survival (OS) and disease-free survival (DFS) were analyzed retrospectively. SDC was classified into five subtypes using a method similar to that used for breast cancer. Results: Anti-AR, HER2, and EGFR were positive in 23 (71.9%), 14 (43.8%), and 26 (81.3%) cases, respectively. One or more of these 3 factors were positive in 30 (93.8%) cases. The Ki-67 labeling index was greater than 15% in all cases. While molecular status did not correlate with OS, EGFR and AR positivity were significantly associated with DFS in univariate analysis. Multivariate analysis revealed that EGFR was the only independent predictor of DFS. Conclusions: The statuses of some molecules are useful to predict DFS in patients with SDC. Ki-67 overexpression suggests that cytotoxic agents are effective for SDC. Since the majority of SDCs express AR, HER2, and/or EGFR, assessing and targeting these molecules are promising strategies to improve the prognosis of unresectable, metastatic or recurrent SDC, and a classification system according to the molecular expression status may be useful to select appropriate therapy. Japan Society of Clinical Oncology, 2014 Salivary duct carcinoma nationallicence Androgen receptor nationallicence HER2 nationallicence Ki-67 nationallicence EGFR nationallicence Masubuchi Tatsuo Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut Tada Yuichiro Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut Maruya Shin-ichiro Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut Osamura Yoshiyuki Center for Diagnostic Pathology, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut Kamata Shin-etsu Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut Miura Kouki Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut Fushimi Chihiro Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut Takahashi Hideaki Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut Kawakita Daisuke Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan aut Kishimoto Seiji Department of Head and Neck Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8519, Tokyo, Japan aut Nagao Toshitaka Department of Anatomic Pathology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, 160-0023, Tokyo, Japan aut International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 35-44 1341-9625 20:1<35 2015 20 10147 https://doi.org/10.1007/s10147-014-0674-6 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0674-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Masubuchi Tatsuo Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut NATIONALLICENCE 700 1- Tada Yuichiro Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut NATIONALLICENCE 700 1- Maruya Shin-ichiro Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut NATIONALLICENCE 700 1- Osamura Yoshiyuki Center for Diagnostic Pathology, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut NATIONALLICENCE 700 1- Kamata Shin-etsu Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut NATIONALLICENCE 700 1- Miura Kouki Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut NATIONALLICENCE 700 1- Fushimi Chihiro Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut NATIONALLICENCE 700 1- Takahashi Hideaki Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-ku, 108-8239, Tokyo, Japan aut NATIONALLICENCE 700 1- Kawakita Daisuke Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, 467-8601, Nagoya, Japan aut NATIONALLICENCE 700 1- Kishimoto Seiji Department of Head and Neck Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8519, Tokyo, Japan aut NATIONALLICENCE 700 1- Nagao Toshitaka Department of Anatomic Pathology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, 160-0023, Tokyo, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 35-44 1341-9625 20:1<35 2015 20 10147